Tesamorelin vs NA-Semax Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →NA-Semax Amidate
NA-Semax Amidate (N-Acetyl Semax Amidate) is a modified version of Semax with enhanced stability and potency. Also known as NASA, it provides stronger and longer-lasting nootropic effects than standard Semax.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | NA-Semax Amidate |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Maintains Semax's core actions on BDNF, NGF, and monoamine systems with improved pharmacokinetics. The modifications enhance CNS penetration and extend duration of action. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Intranasal: 100-600mcg 1-2 times daily. Start with lower doses as it's more potent than standard Semax. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Intranasal spray is most common. Can be used sublingually. More stable than standard Semax in solution. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | May cause irritability, hair shedding (rare), or overstimulation at high doses. Generally well-tolerated. |
| Best For |